Nelin L D, Hoffman G M
Section of Neonatology, Medical College of Wisconsin, Milwaukee, USA.
Pediatr Clin North Am. 1998 Jun;45(3):531-48. doi: 10.1016/s0031-3955(05)70026-2.
Inhaled nitric oxide (NO) clearly decreased pulmonary vascular resistance in pediatric patients with pulmonary hypertension, regardless of the underlying origin of the pulmonary hypertension. In persistent pulmonary hypertension of the neonate (PPHN) and CHD, the use of inhaled NO appears to improve the outcome of these patients. In acute respiratory distress syndrome (ARDS) and surfactant deficiency the role of inhaled NO therapy remains unclear. The use of inhaled NO is safe in a carefully monitored setting with a delivery system designed to minimize the generation of NO2.
吸入一氧化氮（NO）可显著降低患有肺动脉高压的儿科患者的肺血管阻力，无论肺动脉高压的潜在病因是什么。在新生儿持续性肺动脉高压（PPHN）和先天性心脏病（CHD）中，吸入NO的使用似乎可改善这些患者的预后。在急性呼吸窘迫综合征（ARDS）和表面活性剂缺乏症中，吸入NO治疗的作用仍不明确。在精心监测的环境中，使用设计用于尽量减少二氧化氮生成的输送系统时，吸入NO是安全的。
